Azzalini L, Baber U, Johal GS, et al. - Since it is not clear if contemporary bioresorbable-polymer drug-eluting stents (BP-DES) confer better results than durable-polymer DES (DP-DES), therefore, researchers herein assessed three everolimus-eluting stents (EES) for complex percutaneous coronary intervention (PCI), focusing on 1-year outcomes. They analyzed patients receiving PCI with cobalt-chromium (CoCr)-DP-EES (Xience), platinum-chromium (PtCr)-DP-EES (Promus), or PtCr-BP-EES (Synergy) at one high-volume institution between 2015 and 2017. One-year major adverse cardiac events (MACE), defined as a composite of death, myocardial infarction, and target-vessel revascularization, was set as the primary endpoint. MACE rates at 1 year were estimated to be 8.9% for CoCr-DP-EES vs 8.9% for PtCr-DP-EES vs 8.6% for PtCr-BP-EES. Overall, findings demonstrated that the observed rates of MACE and definite/probable stent thrombosis, at 1 year, were comparable among patients receiving PCI with CoCr-DP-EES, PtCr-DP-EES, and PtCr-BP-EES. No change in outcomes was noted in patients receiving complex PCI.